A standing platform for cancer drug development using ctDNA-based evidence of recurrence.

Saved in:
Bibliographic Details
Title: A standing platform for cancer drug development using ctDNA-based evidence of recurrence.
Authors: Medford AJ; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA, USA., Carmeli AB; Science for America, Cambridge, MA, USA., Ritchie A; Science for America, Cambridge, MA, USA., Wagle N; Genentech, South San Francisco, CA, USA., Garraway L; Genentech, South San Francisco, CA, USA., Lander ES; Broad Institute of MIT and Harvard, Cambridge, MA, USA. eric@broadinstitute.org.; Science for America, Cambridge, MA, USA. eric@broadinstitute.org.; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. eric@broadinstitute.org.; Department of Systems Biology, Harvard Medical School, Boston, MA, USA. eric@broadinstitute.org., Parikh A; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA. Aparna.Parikh@mgh.harvard.edu.
Source: Nature reviews. Cancer [Nat Rev Cancer] 2024 Nov; Vol. 24 (11), pp. 810-821. Date of Electronic Publication: 2024 Sep 30.
Publication Type: Journal Article; Review
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101124168 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-1768 (Electronic) Linking ISSN: 1474175X NLM ISO Abbreviation: Nat Rev Cancer Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-1768
DOI:10.1038/s41568-024-00742-2